NSCLC, metastaticCheckMate 026: a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC
© The European Society for Medical Oncology 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.comBackground: Nivolumab improves OS compared with docetaxel in previously treate...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
13 October 2016
|
| In: |
Annals of oncology
Year: 2016, Jahrgang: 27 |
| ISSN: | 1569-8041 |
| DOI: | 10.1093/annonc/mdw435.39 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1093/annonc/mdw435.39 Verlag, kostenfrei, Volltext: https://academic.oup.com/annonc/article/27/suppl_6/LBA7_PR/2800548 
|
| Verfasserangaben: | M. Socinski, B. Creelan, L. Horn, M. Reck, L. Paz-Ares, M. Steins, E. Felip, M. van den Heuvel, T.E. Ciuleanu, F. Badin, N. Ready, T.J. N. Hiltermann, S. Nair, R. Juergens, S. Peters, E. Minenza, W.J. Geese, P. Bhagavatheeswaran, A. Chen, D.P. Carbone |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1565247612 | ||
| 003 | DE-627 | ||
| 005 | 20230427142110.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171110s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/annonc/mdw435.39 |2 doi | |
| 035 | |a (DE-627)1565247612 | ||
| 035 | |a (DE-576)495247618 | ||
| 035 | |a (DE-599)BSZ495247618 | ||
| 035 | |a (OCoLC)1340981717 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Socinski, Mark A. |e VerfasserIn |0 (DE-588)1033568120 |0 (DE-627)741616866 |0 (DE-576)381189562 |4 aut | |
| 245 | 1 | 0 | |a NSCLC, metastaticCheckMate 026 |b a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC |c M. Socinski, B. Creelan, L. Horn, M. Reck, L. Paz-Ares, M. Steins, E. Felip, M. van den Heuvel, T.E. Ciuleanu, F. Badin, N. Ready, T.J. N. Hiltermann, S. Nair, R. Juergens, S. Peters, E. Minenza, W.J. Geese, P. Bhagavatheeswaran, A. Chen, D.P. Carbone |
| 264 | 1 | |c 13 October 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.11.2017 | ||
| 520 | |a © The European Society for Medical Oncology 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissionsoup.comBackground: Nivolumab improves OS compared with docetaxel in previously treated NSCLC. In a phase 1 study (CheckMate 012), nivolumab showed promising activity and manageable safety as monotherapy and in combination with ipilimumab in treatment naive advanced NSCLC. CheckMate 026 (NCT02041533), an open-label, randomized phase 3 study, evaluated the efficacy of nivolumab vs IC PT-DC as first-line therapy in stage IV/recurrent PD-L1-positive NSCLC.Methods: Patients with histologically confirmed and previously untreated stage IV or recurrent NSCLC, ECOG PS 0-1, and PD-L1 positivity were randomized 1:1 to receive nivolumab 3 mg/kg IV Q2W or IC PT-DC (histology-based) Q3W (up to 6 cycles) until disease progression or unacceptable toxicity. Patients with EGFR/ALK mutations sensitive to targeted therapy were excluded. Patients on IC PT-DC... | ||
| 700 | 1 | |a Steins, Martin |d 1971- |e VerfasserIn |0 (DE-588)121323900 |0 (DE-627)705384837 |0 (DE-576)292647379 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 27(2016, Supplement 6) Artikel-Nummer LBA7_PR, 1 Seite |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a NSCLC, metastaticCheckMate 026 a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC |
| 773 | 1 | 8 | |g volume:27 |g year:2016 |g supplement:Supplement 6 |a NSCLC, metastaticCheckMate 026 a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/annonc/mdw435.39 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://academic.oup.com/annonc/article/27/suppl_6/LBA7_PR/2800548 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171110 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 121323900 |a Steins, Martin |m 121323900:Steins, Martin |d 910000 |d 950000 |d 950900 |e 910000PS121323900 |e 950000PS121323900 |e 950900PS121323900 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 6 | ||
| 999 | |a KXP-PPN1565247612 |e 2986949819 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.1093/annonc/mdw435.39"],"eki":["1565247612"]},"title":[{"title_sort":"NSCLC, metastaticCheckMate 026","title":"NSCLC, metastaticCheckMate 026","subtitle":"a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC"}],"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"13 October 2016"}],"name":{"displayForm":["M. Socinski, B. Creelan, L. Horn, M. Reck, L. Paz-Ares, M. Steins, E. Felip, M. van den Heuvel, T.E. Ciuleanu, F. Badin, N. Ready, T.J. N. Hiltermann, S. Nair, R. Juergens, S. Peters, E. Minenza, W.J. Geese, P. Bhagavatheeswaran, A. Chen, D.P. Carbone"]},"person":[{"given":"Mark A.","family":"Socinski","role":"aut","roleDisplay":"VerfasserIn","display":"Socinski, Mark A."},{"roleDisplay":"VerfasserIn","display":"Steins, Martin","role":"aut","family":"Steins","given":"Martin"}],"recId":"1565247612","language":["eng"],"relHost":[{"origin":[{"dateIssuedDisp":"1990-","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"id":{"eki":["320428796"],"zdb":["2003498-2"],"issn":["1569-8041"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"pubHistory":["1.1990 -"],"part":{"year":"2016","volume":"27","text":"27(2016, Supplement 6) Artikel-Nummer LBA7_PR, 1 Seite"},"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"NSCLC, metastaticCheckMate 026 a phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLCAnnals of oncology","note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"language":["eng"],"corporate":[{"roleDisplay":"Herausgebendes Organ","display":"European Society for Medical Oncology","role":"isb"}],"recId":"320428796"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 10.11.2017"]} | ||
| SRT | |a SOCINSKIMANSCLCMETAS1320 | ||